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For those of us that treat cancer, it was impossible to understand the resistance against
gender-neutral human papilloma virus (HPV) vaccination. The incidence of potentially HPV-
related head and neck squamous cell carcinomas has been rising, especially in males1,2. The
other, non-cervical HPV driven cancers are also increasing in incidence. Boys couldn’t be
vaccinated by the NHS, unlike girls who were covered by a national vaccination programme.
Australia agreed to vaccinate boys with the quadrivalent vaccine at ages 12-13 with a catch
up at 14-15 during 2014, despite evidence that its geography would make “herd immunity”
more likely. The UK excluded boys from this preventative program for malignant disease,
despite its geography making “herd immunity” far less likely to be effective.
The government’s vaccination advisory committee, JCVI (Joint Committee on Vaccination
and Immunisation) has been considering whether boys should be included in the vaccination
programme and issued the 2017 interim report3. The JCVI was consulting with stakeholder
groups on this interim report after serious concerns that its recommendations were
discriminatory were raised by influential professional groups like the Cancer Services
2Committee of the RCS England and public special interest groups.  The majority of cancer
treating clinicians welcome the official announcement that boys will now been included in
the vaccination programme.
The actual cost of annual vaccination is estimated to be quarter of the cost of treatment of just
HPV driven oropharyngeal cancer. Often in the NHS clinicians spend hours trying to provide
a comprehensive business case for a new device or technique. However, it was not clear what
we were trying to cost, when evaluating the cost-effectiveness of the HPV vaccine. An
attempt to cost the human suffering from the cancer and its treatment, the price of cancer on
families, patient working hours lost, costs of treatment and survivorship, was a fruitless task.
The cost in human and fiscal terms of HPV related oropharyngeal and other non-cervical
cancers has been grossly underestimated. Only now does the JCVI appear to recognise this.
Patient reported outcomes (PRO’s) are often used in oncology to evaluate disease and
treatment. Regarding HPV vaccination, the majority of parents are motivated to protect their
children and prevent disease4. Clinicians have a duty to provide unambiguous information in
a timely manner and be in a position to address parental concerns regarding vaccine safety.
Data regarding HPV vaccine safety is available and hence this is not argument that can be
used against vaccination. The argument that high levels of vaccine uptake in females can
provide herd immunity for most males, has been taking into account in British government
decision making. The uptake of HPV vaccine is dropping worldwide5. A recent review
indicated suboptimal levels of HPV vaccine uptake6. This in addition to the free movement
within Europe renders the ‘herd protection’ arguments invalid.
3Now that gender neutral vaccination is a reality the road ahead is not easy. Well-designed
prospective research is essential in order to understand the role of the vaccine in prevention
and possibly treatment of established HPV driven cancers7. This may have an impact in
health related quality of life and the overall survival.
Conflict of interest: The authors have no conflict of interest to declare
References
1. Potentially HPV-related head and neck cancers. NCIN Data Briefing.
http://www.ncin.org.uk/publications/data_briefings/potentially_hpv_related_head
_and_neck_cancers
2. D A Mitchell, R Audisio, G Cruickshank, S Cannon, T Gill, A Hayes, S Kehoe, J
McGuigan, B Powell, N Price, N Roland and L Wyld. "Boys in the UK should be
offered HPV vaccine"   BMJ. 2014; 348: 7962, 23.
3. JCVI Interim Statement on extending HPV Vaccination to Adolescent Boys
(2017).
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attac
hment_data/file/630125/Extending_HPV_Vaccination.pdf
4. Independent Cancer Taskforce. Achieving world-class cancer outcomes, a
strategy for England 2015-2020. URL: https://www.england.nhs.uk/wp-
content/.../item-7-cancer-strategy.pdf
45. Marshall S, Fleming A, Moore AC, Sahm LJ. Views of parents regarding human
papillomavirus vaccination: A systematic review and meta-ethnographic synthesis
of qualitative literature. Res Social Adm Pharm. 2018 May 22. pii: S1551-
7411(18)30257-2.
6. Newman PA, Logie CH, Lacombe-Duncan A, Baiden P, Tepjan S, Rubincam C,
Doukas N, Asey F. Parents' uptake of human papillomavirus vaccines for their
children: a systematic review and meta-analysis of observational studies. BMJ
Open. 2018 Apr 20;8(4):e019206.
7. Nugent M, Endersby S, Burns A. Vaccination after treatment of patients with
human papillomavirus-positive oral and oropharyngeal disease - what are we
waiting for? Br J Oral Maxillofac Surg. 2016 Jun;54(5):590.
